Why Aurinia Pharmaceuticals Stock Is Crashing Today

·2 min read
Why Aurinia Pharmaceuticals Stock Is Crashing Today

Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH), an early commercial-stage biotech, are down by 17% in after-hours trading Thursday afternoon. The biotech's stock is cratering in response to the company's 2021 first-quarter earnings report released after the closing bell today. Investors appear to be backing away from Aurinia today for one simple reason: Sales of the biotech's newly approved lupus nephritis medication Lupkynis (aka voclosporin) failed to break even $1 million during the first quarter of 2021.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting